Sorafenib in the treament of metastatic renal cell carcinoma: preliminary result of 20 cases

Hai-liang ZHANG,Ding-wei YE,Xu-dong YAO,Shi-lin ZHANG,Bo DAI,Yi-jun SHEN,Yao ZHU
DOI: https://doi.org/10.3969/j.issn.1007-3639.2008.02.012
2008-01-01
Abstract:Background and purpose:most renal cell carcinomas(RCC)are in late stage at diagnosis.The effective strategy for the disease is limited.The molecular targeted drug for RCC has been proved as a potential currative method.Our paper is to investigate the efficacy and side effects of sorafenib in the treatment of metastatic RCC in our center.Methods:From Mar 2006 to Apr 2007,20 patients with metastatic renal cell carcinoma were given oral sorafenib 400 mg twice daily as either the first line or second line treatment.The pathological diagnoses of primary tumors were clear cell carcinoma in 19 patients and papillary carcinoma in one patient.The metastatic sites of all the patients included 16 in lungs,5 in bone,4 in retroperitoneal nodes,2 in liver,one in adrenal gland and one in superior clavicular lymph nodes.Results:3 patients have not been assessed because of only one month's treatment.CR or PR has not been observed in our group.15(88.2%)patients achieved SD,in which 3 have stable disease for nearly 12 months and tumor shrinkage was seen in 11 cases(64.7%).2 patients had progressive disease.Common side effects were hand-foot skin reaction,alopecia,diarrhea and hypertension.Conclusions:As the first molecular drug approved for metastatic renal cell carcinoma,Sorafenib was effective in both controlling tumor growth and relieving the symptoms associated with disease progression,and its toxicity was relatively minor as compared to that of other systemic chemotherapy.Further follow up is needed to analyse the impact on the survival of patients.
What problem does this paper attempt to address?